All In Biotech

Drug Trial Radar · NCT07933133

A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Apr 1, 2029

Study completion Feb 1, 2030

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, blinded, placebo- and active-controlled Phase II study to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of SYH9061 at different doses and dosing frequencies in patients with IPF, and to determine the optimal recommended dose for Phase III confirmatory studies.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • SYH9061Drug

    Administered at the dose specified in the protocol.

  • PlaceboDrug

    Administered at the dose specified in the protocol.

  • Ofev®Drug

    Administered at the dose specified in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in FVC from baseline (mL)Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.